NO307029B1 - Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier - Google Patents

Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier

Info

Publication number
NO307029B1
NO307029B1 NO19952624A NO952624A NO307029B1 NO 307029 B1 NO307029 B1 NO 307029B1 NO 19952624 A NO19952624 A NO 19952624A NO 952624 A NO952624 A NO 952624A NO 307029 B1 NO307029 B1 NO 307029B1
Authority
NO
Norway
Prior art keywords
imidazol
dihydro
chloro
amino
treatment
Prior art date
Application number
NO19952624A
Other languages
English (en)
Norwegian (no)
Other versions
NO952624L (no
NO952624D0 (no
Inventor
Dieter Ziegler
Reinhard Brueckner
Elbert Kaan
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO952624D0 publication Critical patent/NO952624D0/no
Publication of NO952624L publication Critical patent/NO952624L/no
Publication of NO307029B1 publication Critical patent/NO307029B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
NO19952624A 1994-07-01 1995-06-30 Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier NO307029B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (3)

Publication Number Publication Date
NO952624D0 NO952624D0 (no) 1995-06-30
NO952624L NO952624L (no) 1996-01-02
NO307029B1 true NO307029B1 (no) 2000-01-31

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19952624A NO307029B1 (no) 1994-07-01 1995-06-30 Anvendelse av 4-klor-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-metoksy-2-metylpyrimidin til fremstilling av farmasoytiske preparater for behandling av hyperglykemier

Country Status (23)

Country Link
US (1) US5712283A (fr)
EP (1) EP0689837B1 (fr)
JP (1) JP3841846B2 (fr)
KR (1) KR100366130B1 (fr)
CN (1) CN1092961C (fr)
AT (1) ATE210444T1 (fr)
AU (1) AU691580B2 (fr)
CA (1) CA2152998C (fr)
CZ (1) CZ287563B6 (fr)
DE (2) DE4423177A1 (fr)
DK (1) DK0689837T3 (fr)
DZ (1) DZ1894A1 (fr)
ES (1) ES2167385T3 (fr)
FI (1) FI117374B (fr)
HU (1) HU226946B1 (fr)
IL (1) IL113411A (fr)
NO (1) NO307029B1 (fr)
NZ (1) NZ270990A (fr)
PT (1) PT689837E (fr)
RU (1) RU2145857C1 (fr)
SK (1) SK282227B6 (fr)
UA (1) UA27954C2 (fr)
ZA (1) ZA954691B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
TR199802496T2 (xx) * 1996-06-06 1999-02-22 Eli Lilly And Company Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
NO980546L (no) * 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
WO1999020279A1 (fr) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentialisation de produits pharmaceutiques
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE50009220D1 (de) * 1999-02-01 2005-02-17 Solvay Pharm Gmbh Verwendung von moxonidin zur behandlung nach herzinfarkt
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
RU2219930C2 (ru) * 2001-09-24 2003-12-27 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения заболеваний печени
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
MXPA06004029A (es) * 2003-10-10 2006-06-28 Solvay Pharm Gmbh Composicion farmaceutica que comprende un agonista del receptor de imidazolina selectivo i1 y un bloqueante del receptor de angiotensina ii.
RU2426543C1 (ru) * 2010-05-24 2011-08-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН НИИ фармакологии СО РАМН Способ дифференцированного назначения моксонидина у пациентов с артериальной гипертензией на фоне метаболического синдрома
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
AU691580B2 (en) 1998-05-21
RU2145857C1 (ru) 2000-02-27
EP0689837A3 (fr) 1996-06-05
DK0689837T3 (da) 2002-03-11
SK74995A3 (en) 1996-05-08
ATE210444T1 (de) 2001-12-15
US5712283A (en) 1998-01-27
EP0689837B1 (fr) 2001-12-12
SK282227B6 (sk) 2001-12-03
CN1092961C (zh) 2002-10-23
CN1122224A (zh) 1996-05-15
FI117374B (fi) 2006-09-29
HU226946B1 (en) 2010-03-29
AU1775795A (en) 1996-01-18
NO952624L (no) 1996-01-02
DE59509928D1 (de) 2002-01-24
PT689837E (pt) 2002-04-29
FI953256A0 (fi) 1995-06-30
KR960003729A (ko) 1996-02-23
CA2152998C (fr) 2002-09-03
HU9501900D0 (en) 1995-08-28
ES2167385T3 (es) 2002-05-16
JPH0840906A (ja) 1996-02-13
CZ139395A3 (en) 1996-01-17
NO952624D0 (no) 1995-06-30
DZ1894A1 (fr) 2002-02-17
JP3841846B2 (ja) 2006-11-08
IL113411A (en) 1999-07-14
NZ270990A (en) 1997-06-24
UA27954C2 (uk) 2000-10-16
CA2152998A1 (fr) 1996-01-02
HUT72599A (en) 1996-05-28
ZA954691B (en) 1996-01-29
KR100366130B1 (ko) 2003-03-26
CZ287563B6 (en) 2000-12-13
IL113411A0 (en) 1995-07-31
FI953256L (fi) 1996-01-02
EP0689837A2 (fr) 1996-01-03
DE4423177A1 (de) 1996-01-04

Similar Documents

Publication Publication Date Title
AU627906B2 (en) Uracil derivatives and herbicides containing the same as active ingredient
PT689837E (pt) Composicoes farmaceuticas com efeito antihiperglicemico
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
ATE75722T1 (de) Neue diphenylpropylamin-derivate, ihre herstellung sowie ihre pharmazeutische verwendung.
NO940523L (no) Nye pyrazin-derivater
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
RU95109157A (ru) Противогипергликемически эффективная фармацевтическая композиция
CA2038025A1 (fr) Derives de l'alkylenedioxybenzene optiquement actifs et leur utilisation a des fins therapeutiques
ATE127343T1 (de) Pharmazeutische zubereitung von roxindol oder carmoxirol mit vorgeqüollener stärke.
NZ238022A (en) Indole derivatives and pharmaceutical compositions
ES2117114T3 (es) Nuevos derivados de tiaxolidin-diona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE116296T1 (de) Säureadditionssalze einer optisch aktiven alaninanilidverbindung und diese enthaltende, pharmazeutische zusammensetzungen.
ES2121071T3 (es) Compuestos de oxazolidina y su empleo como medicamentos.
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
DK0499586T3 (da) Substitueret benzofuranylpiperidin som nootropikum

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE

MM1K Lapsed by not paying the annual fees